Premature ovarian insufficiency: an International Menopause Society White Paper

References

• Bachelot A, Nicolas C, Bidet M, et al. Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency. Clin Endocrinol 2017;86:223–8
   PubMed Web of Science ®Google Scholar
• Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604–6
   PubMed Web of Science ®Google Scholar
• Lagergren K, Hammar M, Nedstrand E, Bladh M, Sydsiö G. The prevalence of primary ovarian insufficiency in Sweden; a national register study. BMC Womens Health 2018;18:175
   PubMed Web of Science ®Google Scholar
• Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric 2019;22:403–11
   PubMed Web of Science ®Google Scholar
• Webber L, Davies M, Anderson R, et al. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016;31:926–37
   PubMed Web of Science ®Google Scholar
• Nelson LM. Clinical Practice. Primary ovarian insufficiency. N Engl J Med 2009;360:606–14
   PubMed Web of Science ®Google Scholar
• Rebar RW. Premature ovarian failure. Obstet Gynecol 2009;113:1355–63
   PubMed Web of Science ®Google Scholar
• Vujovic S. Aetiology of premature ovarian failure. Menopause Int 2009;15:72–5
   PubMedGoogle Scholar
• Ford EA, Beckett EL, Roman SD, McLaughlin EA, Sutherland JM. Advances in human primordial follicle activation and premature ovarian insufficiency. Reproduction 2020;159:R15–R29
   PubMed Web of Science ®Google Scholar
• Huhtaniemi I, Alevizaki M. Gonadotrophin resistance. Best Pract Res Clin Endocrinol Metab 2006;20:561–76
   PubMed Web of Science ®Google Scholar
• Hoshino A, Horvath S, Sridhar A, Chitsazan A, Reh TA. Synchrony and asynchrony between an epigenetic clock and developmental timing. Sci Rep 2019;9:3770
   PubMed Web of Science ®Google Scholar
• Xu X, Jones M, Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort. Hum Reprod 2020;35:203–11
   PubMed Web of Science ®Google Scholar
• Van Kasteren YM, Hundscheid RD, Smits AP, Cremers FP, van Zonneveld P, Braat DD. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod 1999;14:2455–9
   PubMed Web of Science ®Google Scholar
• Jiao X, Qin C, Li J, et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum Reprod 2012;27:2201–7.
   PubMed Web of Science ®Google Scholar
• Heddar A, Dessen P, Flatters D, Misrahi M. Novel STAG3 mutations in a Caucasian family with primary ovarian insufficiency. Mol Genet Genomics 2019;294:1527–34
   PubMed Web of Science ®Google Scholar
• Tucker EJ, Grover SR, Bachelot A, Touraine P, Sinclair AH. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum. Endocr Rev 2016;37:609–35
   PubMed Web of Science ®Google Scholar
• Schlessinger D, Herrera L, Crisponi L, et al. Genes and translocations involved in POF. Am J Med Genet 2002;111:328–33
   PubMed Web of Science ®Google Scholar
• Rossetti R, Ferrari I, Bonomi M, Persani L. Genetics of primary ovarian insufficiency. Clin Genet 2017;91:183–98
   PubMed Web of Science ®Google Scholar
• Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec 1966;155:369–83
   PubMedGoogle Scholar
• Castronovo C, Rossetti R, Rusconi D, et al. Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome. Hum Reprod 2014;29:368–79
   PubMed Web of Science ®Google Scholar
• Gravholt CH, Andersen NH, Conway GS, et al. International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017;177:G1–70
   PubMed Web of Science ®Google Scholar
• Liu AX, Shi HY, Cai ZJ, et al. Increased risk of gonadal malignancy and prophylactic gonadectomy: a study of 102 phenotypic female patients with Y chromosome or Y-derived sequences. Hum Reprod 2014;29:1413–19
   PubMed Web of Science ®Google Scholar
• Rousseau F, Rouillard P, Morel ML, et al. Prevalence of carriers of premutation-size alleles of the FMR1 gene-and implications for the population genetics of the fragile X syndrome. Am J Hum Genet 1995;57:1006–18
   PubMed Web of Science ®Google Scholar
• Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000;97:189–94
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists Committee on Genetics. ACOG committee opinion. No. 338: screening for fragile X syndrome. Obstet Gynecol 2006;107:1483–5
   PubMedGoogle Scholar
• Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107–34
   PubMed Web of Science ®Google Scholar
• Bakalov VK, Anasti JN, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril 2005;84:958–65
   PubMed Web of Science ®Google Scholar
• Silva CA, Yamakami LY, Aikawa NE, et al. Autoimmune primary ovarian insufficiency. Autoimmun Rev 2014;13:427–30
   PubMed Web of Science ®Google Scholar
• Morrison JC, Givens JR, Wiser WL, Fish SA. Mumps oophoritis: a cause of premature menopause. Fertil Steril 1975;26:655–9
   PubMed Web of Science ®Google Scholar
• Tariq S, Anderson J, Burns F, Delpech V, Gilson R, Sabin C. The menopause transition in women living with HIV: current evidence and future avenues of research. J Virus Erod 2016;2:114–16
   PubMed Web of Science ®Google Scholar
• Ebrahimi M, Asbagh A. F. Pathogenesis and causes of premature ovarian failure: an update. Int J Fertil Steril 2011;5:54–65
   PubMed Web of Science ®Google Scholar
• Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983;117:651–8
   PubMed Web of Science ®Google Scholar
• Vabre P, Gatimel N, Moreau J, et al. Environmental pollutants, a possible etiology for premature ovarian insufficiency: a narrative review of animal and human data. Environ Health 2017;16:37
   PubMed Web of Science ®Google Scholar
• Thakur M, Feldman G, Puscheck E. Primary ovarian insufficiency in classic galactosemia: current understanding and future research opportunities. J Assist Reprod Genet 2018;35:3–16
   PubMed Web of Science ®Google Scholar
• Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222–9
   PubMed Web of Science ®Google Scholar
• Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update 2019;25:673–93
   PubMed Web of Science ®Google Scholar
• Nguyen QN, Zerafa N, Liew SH, Findlay JK, Hickey M, Hutt KJ. Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes. Mol Hum Reprod 2019;25:433–44
   PubMed Web of Science ®Google Scholar
• Chen H, Xiao L, Li J, Cui L, Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2019;3:CD008018
   PubMed Web of Science ®Google Scholar
• Guida M, Castaldi MA, Rosamilio R, Giudice V, Orio F, Selleri C. Reproductive issues in patients undergoing hematopoietic stem cell transplantation: an update. J Ovarian Res 2016;9:72
   PubMed Web of Science ®Google Scholar
• Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890–6
   PubMed Web of Science ®Google Scholar
• Mishra GD, Chung HF, Cano A, et al. EMAS position statement: predictors of premature and early natural menopause. Maturitas 2019;123:82–8
   PubMed Web of Science ®Google Scholar
• Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:386–405
   PubMed Web of Science ®Google Scholar
• Deeks AA, Gibson-Helm M, Teede H, Vincent A. Premature menopause: a comprehensive understanding of psychosocial aspects. Climacteric 2011;14:565–72
   PubMed Web of Science ®Google Scholar
• Singer D, Mann E, Hunter MS, Pitkin J, Panay N. The silent grief: psychosocial aspects of premature ovarian failure. Climacteric 2011;14:428–37
   PubMed Web of Science ®Google Scholar
• Vujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas 2010;67:91–3
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• NICE Guideline[NG23]: Menopause diagnosis and management. Available from: https://www.nice.org.uk/guidance/ng23 [last accessed 13 April 2020].
   Google Scholar
• Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 2017;87:58–64
   PubMed Web of Science ®Google Scholar
• Nyström A, Mörse H, Nordlöf H, et al. Anti-müllerian hormone compared with other ovarian markers after childhood cancer treatment. Acta Oncol 2019;58:218–24
   PubMed Web of Science ®Google Scholar
• Nelson SM, Klein BM, Arce JC. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. Fertil Steril 2015;103:923–30
   PubMed Web of Science ®Google Scholar
• Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet 2019;36:2207–15
   PubMed Web of Science ®Google Scholar
• Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond) 2015;11:169–82
   PubMedGoogle Scholar
• Nappi RE, Cucinella L, Martini E, et al. Sexuality in premature ovarian insufficiency. Climacteric 2019;22:289–95
   PubMed Web of Science ®Google Scholar
• Graziottin A. Menopause and sexuality: key issues in premature menopause and beyond. Ann N Y Acad Sci 2010;1205:254–61
   PubMed Web of Science ®Google Scholar
• van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15:23–31
   PubMed Web of Science ®Google Scholar
• Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. Menopause 2004;11:766–77
   PubMed Web of Science ®Google Scholar
• Nappi RE, Polatti F. The use of estrogen therapy in women’s sexual functioning (CME). J Sex Med 2009;6:603–16
   PubMed Web of Science ®Google Scholar
• De Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011;18:262–6
   PubMed Web of Science ®Google Scholar
• Pacello PC, Yela DA, Rabelo S, Giraldo PC, Benetti-Pinto CL. Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric 2014;17:342–7
   PubMed Web of Science ®Google Scholar
• Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause 2018;25:837–47
   PubMed Web of Science ®Google Scholar
• Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an international menopause society white paper. Climacteric 2018;21:415–27
   PubMed Web of Science ®Google Scholar
• Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. J Psychosom Obstet Gynaecol 2000;21:167–74
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Luff JA, Haq NA, et al. Depression in women with spontaneous 46,XX primary ovarian insufficiency. J Clin Endocrinol Metab 2011;96:E278–87
   PubMed Web of Science ®Google Scholar
• Orshan SA, Ventura JL, Covington SN, Vanderhoof VH, Troendle JF, Nelson LM. Women with spontaneous 46,XX primary ovarian insufficiency (hypergonadotropic hypogonadism) have lower perceived social support than control women. Fertil Steril 2009;92:688–93
   PubMed Web of Science ®Google Scholar
• Ventura JL, Fitzgerald OR, Koziol DE, et al. Functional well-being is positively correlated with spiritual well-being in women who have spontaneous premature ovarian failure. Fertil Steril 2007;87:584–90
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Cardoso GM, Ross JL, et al. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. JAMA 2006;295:1374–6
   PubMed Web of Science ®Google Scholar
• Mann E, Singer D, Pitkin J, Panay N, Hunter MS. Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric 2012;15:481–9
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, Geda YE, et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2018;25:1275–85
   PubMed Web of Science ®Google Scholar
• Laughlin-Tommaso SK, Satish A, Khan Z, Smith CY, Rocca WA, Stewart EA. Long-term risk of de novo mental health conditions after hysterectomy with ovarian conservation: a cohort study. Menopause 2020;27:33–42
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Bitzer J, Brandenburg U, et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric 2010;13:103–20
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Premature ovarian insufficiency: working towards an international database. Climacteric 2012;15:295–6
   PubMed Web of Science ®Google Scholar
• Cooper AR, Baker VL, Sterling EW, Ryan ME, Woodruff TK, Nelson LM. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril 2011;95:1890–7
   PubMed Web of Science ®Google Scholar
• Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med 2015;12:189–97
   PubMed Web of Science ®Google Scholar
• Yeganeh L, Boyle JA, Wood A, Teede H, Vincent AJ. Menopause guideline appraisal and algorithm development for premature ovarian insufficiency. Maturitas 2019;130:21–31
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Palla G, Gambacciani M, Simoncini T. Tailored hormonal approach in women with premature ovarian insufficiency. Climacteric 2020;23:3–8
   PubMed Web of Science ®Google Scholar
• Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. Climacteric 2019;22:429–34
   PubMed Web of Science ®Google Scholar
• Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019;7:754–66
   PubMed Web of Science ®Google Scholar
• Chu MC, Rath KM, Huie J, Taylor HS. Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk. Hum Reprod 2003;18:1570–3
   PubMed Web of Science ®Google Scholar
• Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric 2016;19:27–36
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep JE, Heida KV, Bots ML, Hoek A. Cardiovascular disease in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiolog 2016;23:178–86
   PubMed Web of Science ®Google Scholar
• Amagai Y, Ishikawa S, Gotoh T, Kayaba K, Nakamura Y, Kajii E. Age at menopause and mortality in Japan: the Jichi Medical School Cohort Study. J Epidemiol 2006;16:161–8
   PubMed Web of Science ®Google Scholar
• Gallagher LG, Davis LB, Ray RM, et al. Reproductive history and mortality from cardiovascular disease among women textile workers in Shanghai, China. Int J Epidemiol 2011;40:1510–18
   PubMed Web of Science ®Google Scholar
• Jacobsen BK, Heuch I, Kvale G, et al. Age at natural menopause and all-cause mortality: a 37 year follow up of 19 731 Norwegian women. Am J Epidemiol 2003;157:923–9
   PubMed Web of Science ®Google Scholar
• Wu X, Cai H, Kallianpur A, et al. Impact of premature ovarian failure on mortality and morbidity among Chinese women. PLoS One 2014;9:e89597
   PubMed Web of Science ®Google Scholar
• Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019;4:e553–e564
   PubMed Web of Science ®Google Scholar
• Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA 2019;322:2411
   PubMed Web of Science ®Google Scholar
• Ley SH, Li Y, Tobias DK, et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. J Am Heart Assoc 2017;6:pii:e006713
   Web of Science ®Google Scholar
• Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular Traits, and All-Cause Mortality: a systematic review and meta-analysis. JAMA Cardiol 2016;1:767–76
   PubMed Web of Science ®Google Scholar
• Giannini A, Genazzani AR, Simoncini T, The long-term risks of premature ovarian insufficiency. In: Genazzani AR, Tarlatszis B. Ed. Frontiers in Gynecological Endocrinology, vol 3. Ovarian Function and Reproduction – from need to possibilities. Switzerland: Springer; 2016:61–6
   Google Scholar
• Gerval MO, Stevenson J. Establishing the risk related to hormone replacement therapy and cardiovascular disease in women. Clin Pharm 2017;5:7–24
   Google Scholar
• Tsiligiannis S, Panay N, Stevenson JC. Premature ovarian insufficiency and long-term health consequences. Curr Vasc Pharmacol 2019;17:604–9
   PubMed Web of Science ®Google Scholar
• Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716–27
   PubMed Web of Science ®Google Scholar
• Canpolat U, Tokgozoglu L, Yorgun H, et al. The association of premature ovarian failure with ventricular repolarization dynamics evaluated by QT dynamicity. Europace 2013;15:1657–63
   PubMed Web of Science ®Google Scholar
• Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004;89:3907–13
   PubMed Web of Science ®Google Scholar
• Ostberg JE, Storry C, Donald AE, Attar MJ, Halcox JP, Conway GS. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol 2007;66:557–64
   PubMed Web of Science ®Google Scholar
• Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 2009;53:805–11
   PubMed Web of Science ®Google Scholar
• Kuylaksizoglu M, Ipeka S, Kebapcilar L, et al. Risk factors for diabetes mellitus in women with premature ovarian insufficiency. Biol Trace Elim Rep 2013;154:312
   Web of Science ®Google Scholar
• Slijepcevic D, Stozinic S, Vujovic S. Stres i somatizacija. Strucna knjiga. Ur:Vlahovic Z. Beograd 1994;33:1223–35
   Google Scholar
• Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10:143–56
   PubMed Web of Science ®Google Scholar
• Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103–7
   PubMed Web of Science ®Google Scholar
• Marina LV, Ivovic M, Tancic-Gajic M, et al. Luteinizing hormone and insulin resistance in menopausal patients with adrenal incidentalomas: the cause-effect relationship? Clin Endocrinol 2018;88:541–8
   PubMed Web of Science ®Google Scholar
• Guttmann H, Weiner Z, Nikolski E, et al. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clin Endocrinol (Oxf) 2001;54:159–64
   PubMed Web of Science ®Google Scholar
• Bachelot A, Nicolas C, Gricourt S, et al. Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency. PLoS One 2016;11:e0164638
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Lehman A, Nathan NK, Thomson CA, Howard BV. Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the Women’s Health Initiative Clinical Trials. Menopause 2017;24:371–8
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause 2007;14:567–71
   PubMed Web of Science ®Google Scholar
• Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 2009;94:2277–83
   PubMed Web of Science ®Google Scholar
• Shah S, Nguyen HH, Vincent AJ. Care of the adult woman with Turner syndrome. Climacteric 2018;21:428–36
   PubMed Web of Science ®Google Scholar
• Mittal M, Kreatsa M, Narvekar N, Savvas M, Hamoda H. Fertility desires, choice of hormone replacement and the effect of length of time since menopause on bone density in women with premature ovarian insufficiency: a review of 223 consecutive new referrals to a tertiary centre. Post Reprod Health 2014;20:104–11
   PubMedGoogle Scholar
• Vincent AJ, Nguyen HH, Ranasinha S, Vollenhoven B. Increased detection of co-morbidities with evaluation at a dedicated adult Turner syndrome clinic. Climacteric 2017;20:442–7
   PubMed Web of Science ®Google Scholar
• Goh M, Nguyen HH, Khan NN, Milat F, Boyle JA, Vincent AJ. Identifying and addressing osteoporosis knowledge gaps in women with premature ovarian insufficiency and early menopause: a mixed-methods study. Clin Endocrinol 2019;91:498–507
   PubMed Web of Science ®Google Scholar
• Yeganeh L, Boyle J, Teede H, Vincent A. Knowledge and attitudes of health professionals regarding menopausal hormone therapies. Climacteric 2017;20:348–55
   PubMed Web of Science ®Google Scholar
• Richardson A, Haridass S, Ward E, Ayres J, Baskind N. Investigation and treatment of premature ovarian insufficiency: a multi-disciplinary review of practice. Post Reprod Health 2018;24:155–62
   PubMedGoogle Scholar
• Ferrari S, Bianchi ML, Eisman JA, et al. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 2012;23:2735–48
   PubMed Web of Science ®Google Scholar
• Nguyen HH, Wong P, Strauss BJ, Ebeling PR, Milat F, Vincent A. A cross-sectional and longitudinal analysis of trabecular bone score in adults with Turner syndrome. J Clin Endocrinol Metab 2018;103:3792–800
   PubMed Web of Science ®Google Scholar
• 2019 International Society for Clinical Densitometry position statement. Available from: https://www.iscd.org/official-positions/2019-iscd-official-positions-adult [last accessed 7 February 2020].
   Google Scholar
• Kiriakova V, Cooray SD, Yeganeh L, Somarajah G, Milat F, Vincent AJ. Management of bone health in women with premature ovarian insufficiency: systematic appraisal of clinical practice guidelines and algorithm development. Maturitas 2019;128:70–80
   PubMed Web of Science ®Google Scholar
• Burgos N, Cintron D, Latortue-Albino P, et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine 2017;58:413–25
   PubMed Web of Science ®Google Scholar
• Cintron D, Rodriguez-Gutierrez R, Serrano V, Latortue-Albino P, Erwin PJ, Murad MH. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome: a systematic review and meta-analysis. Endocrine 2017;55:366–75
   PubMed Web of Science ®Google Scholar
• Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf) 2010;73:707–14
   PubMed Web of Science ®Google Scholar
• Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 2016;101:3497–505
   PubMed Web of Science ®Google Scholar
• Cleemann L, Holm K, Kobbernagel H, et al. Dosage of estradiol, bone and body composition in Turner syndrome: a 5-year randomized controlled clinical trial. Eur J Endocrinol 2017;176:233–42
   PubMed Web of Science ®Google Scholar
• Tauchmanova L, De Simone G, Musella T, et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37:81–8
   PubMed Web of Science ®Google Scholar
• Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in Turner syndrome: a pilot study. J Clin Endocrinol Metab 2009;94:4820–7
   PubMed Web of Science ®Google Scholar
• Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014;99:3418–26
   PubMed Web of Science ®Google Scholar
• Kurtoglu-Aksoy N, Akhan SE, Bastu E, et al. Implications of premature ovarian failure on bone turnover markers and bone mineral density. Clin Exp Obstet Gynecol 2014;41:149–53
   PubMed Web of Science ®Google Scholar
• Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074–83
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr, Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012;19:272–7
   PubMed Web of Science ®Google Scholar
• Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord 2001;16:830–7
   PubMed Web of Science ®Google Scholar
• Bove R, Secor E, Chibnik LB, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014;82:222–9
   PubMed Web of Science ®Google Scholar
• Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab 2011;96:3864–72
   PubMed Web of Science ®Google Scholar
• Sauer MV. Spontaneous pregnancy in women awaiting oocyte donation. J Reprod Med 1995;40:630–2
   PubMed Web of Science ®Google Scholar
• van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999;5:483–92
   PubMed Web of Science ®Google Scholar
• Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review. Reprod Biomed Online 2019;39:467–76
   PubMed Web of Science ®Google Scholar
• Taylor AE, Adams JM, Mulder JE, Martin KA, Sluss PM, Crowley WF Jr, A randomized, controlled trial of estradiol replacement therapy in women with hypergonadotropic amenorrhea. J Clin Endocrinol Metab 1996;81:3615–21
   PubMed Web of Science ®Google Scholar
• Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pre-treatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril 2007;87:858–61
   PubMed Web of Science ®Google Scholar
• Badawy A, Goda H, Ragab A. Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial. Reprod Biomed Online 2007;15:215–19
   PubMed Web of Science ®Google Scholar
• Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev 2015;11:CD009749
   PubMed Web of Science ®Google Scholar
• Wong QHY, Yeung TWY, Yung SSF, Ko JKY, Li HWR, Ng EHY. The effect of 12-month dehydroepiandrosterone supplementation on the menstrual pattern, ovarian reserve markers, and safety profile in women with premature ovarian insufficiency. J Assist Reprod Genet 2018;35:857–62
   PubMed Web of Science ®Google Scholar
• Mol BW, Barnhart KT. Scratching the endometrium in in vitro fertilization – time to stop. N Engl J Med 2019;380:391–2
   PubMed Web of Science ®Google Scholar
• Hershlag A, Schuster MW. Return of fertility after autologous stem cell transplantation. Fertil Steril 2002;77:419–21
   PubMed Web of Science ®Google Scholar
• Li J, Yu Q, Huang H, et al. Human chorionic plate-derived mesenchymal stem cells transplantation restores ovarian function in a chemotherapy-induced mouse model of premature ovarian failure. Stem Cell Res Ther 2018;9:81
   PubMed Web of Science ®Google Scholar
• Hosseini L, Shirazi A, Naderi MM, et al. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Reprod Biomed Online 2017;35:343–50
   PubMed Web of Science ®Google Scholar
• Hsu CC, Hsu L, Hsu I, Chiu YJ, Dorjee S. Live birth in woman with premature ovarian insufficiency receiving ovarian administration of platelet-rich plasma (PRP) in combination with gonadotropin: a case report. Front Endocrinol 2020;11:50
   PubMed Web of Science ®Google Scholar
• Suzuki N, Yoshioka N, Takae S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod 2015;30:608–15
   PubMed Web of Science ®Google Scholar
• Lee HN, Chang EM. Primordial follicle activation as new treatment for primary ovarian insufficiency. Clin Exp Reprod Med 2019;46:43–9
   PubMedGoogle Scholar
• Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med 2017;377:1657–65
   PubMed Web of Science ®Google Scholar
• Gellert SE, Pors SE, Kristensen SG, Bay-Bjørn AM, Ernst E, Yding Andersen C. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet 2018;35:561–70
   PubMed Web of Science ®Google Scholar
• Mamsen LS, Charkiewicz K, Anderson RA, et al. Characterization of follicles in girls and young women with Turner syndrome who underwent ovarian tissue cryopreservation. Fertil Steril 2019;111:1217–25 e1213
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectome: a committee opinion. Fertil Steril 2019;112:1022–33
   PubMed Web of Science ®Google Scholar
• Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004;428:145–50
   PubMed Web of Science ®Google Scholar
• White YA, Woods DC, Takai Y, Ishihara O, Seki H, Tilly JL. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nat Med 2012;18:413–21
   PubMed Web of Science ®Google Scholar
• Telfer EE, Gosden RG, Byskov AG, et al. On regenerating the ovary and generating controversy. Cell 2005;122:821–2
   PubMed Web of Science ®Google Scholar
• Martin JJ, Woods DC, Tilly JL. Implications and current limitations of oogenesis from female germline or oogonial stem cells in adult mammalian ovaries. Cells 2019;8:93
   Web of Science ®Google Scholar
• Telfer EE, Anderson RA. The existence and potential of germline stem cells in the adult mammalian ovary. Climacteric 2019;22:22–6
   PubMed Web of Science ®Google Scholar
• Zou K, Yuan Z, Yang Z, et al. Production of offspring from a germline stem cell line derived from neonatal ovaries. Nat Cell Biol 2009;11:631–6
   PubMed Web of Science ®Google Scholar
• Clarkson YL, McLaughlin M, Waterfall M, et al. Initial characterisation of adult human ovarian cell populations isolated by DDX4 expression and aldehyde dehydrogenase activity. Sci Rep 2018;8:6953
   PubMed Web of Science ®Google Scholar
• Wang N, Satirapod C, Ohguchi Y, Park ES, Woods DC, Tilly JL. Genetic studies in mice directly link oocytes produced during adulthood to ovarian function and natural fertility. Sci Rep 2017;7:10011
   PubMed Web of Science ®Google Scholar
• Xiong J, Lu Z, Wu M, et al. Intraovarian transplantation of female germline stem cells rescue ovarian function in chemotherapy-injured ovaries. PLoS One 2015;10:e0139824
   PubMed Web of Science ®Google Scholar
• Hikabe O, Hamazaki N, Nagamatsu G, et al. Reconstitution in vitro of the entire cycle of the mouse female germ line. Nature 2016;539:299–303
   PubMed Web of Science ®Google Scholar
• Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open 2017;(2):hox007
   Google Scholar
• Fournier A, Dossus L, Mesrine S, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008. Am J Epidemiol 2014;180:508–17
   PubMed Web of Science ®Google Scholar
• Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012;(2):CD000402
   Google Scholar
• Sturdee DW, Panay N, International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
   PubMed Web of Science ®Google Scholar
• Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016;19:151–61
   PubMed Web of Science ®Google Scholar
• Panay N, Medical Advisory Council of the British Menopause Society. BMS – Consensus statement: bioidentical HRT. Post Reprod Health 2019;25:61–3
   PubMedGoogle Scholar
• Barrett-Connor E, Slone S, Greendale G, et al. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas 1997;27:261–74
   PubMed Web of Science ®Google Scholar
• Mittal M, Savvas M, Arya R, et al. A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review of the literature. Menopause Int 2013;19:127–32
   PubMedGoogle Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159–68
   PubMed Web of Science ®Google Scholar
• Conway GS, Davies M, Merry A. Treatment of Turner’s syndrome. Lancet 1996;348:1590–1
   PubMed Web of Science ®Google Scholar
• Ben-Nagi J, Panay N. Premature ovarian insufficiency: how to improve reproductive outcome? Climacteric 2014;17:242–6
   PubMed Web of Science ®Google Scholar
• Dragojević Dikić S, Vasiljević M, Jovanović A, et al. Premature ovarian insufficiency – novel hormonal approaches in optimizing fertility. Gynecol Endocrinol 2020;36:162–5
   PubMed Web of Science ®Google Scholar
• Bosze P, Toth A, Torok M. Hormone replacement and the risk of breast cancer in Turner’s syndrome. N Engl J Med 2006;355:2599–600
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Farmer RDT. HRT and breast cancer: a million women ride again. Climacteric 2020;23:226–8
   PubMed Web of Science ®Google Scholar
• Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol 2019;153:192–200
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, O’Sullivan MJ, et al. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women’s Health Initiative Hormone Therapy clinical trials. Menopause 2014;21:214–20
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q Research and CPRD databases. BMJ 2019;364:k4810
   PubMed Web of Science ®Google Scholar
• Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update 2012;18:405–19
   PubMed Web of Science ®Google Scholar
• Sassarini J, Lumsden MA. Non-hormonal management of vasomotor symptoms. Climacteric 2013;16:31–6
   PubMed Web of Science ®Google Scholar
• Szabo RA, Marino JL, Hickey M. Managing menopausal symptoms after cancer. Climacteric 2019;22:572–8
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Iatrogenic menopause following gynecological malignancy: time for action! Climacteric 2016;19:1–2
   PubMed Web of Science ®Google Scholar